Czech Republic: an attractive OTC and pharma market in the heart of Europe
The Czech Republic is one of the most attractive consumer healthcare and pharma markets in Central and Eastern Europe. Discover its potential in this article:
With a 2019 market value of US $1,04 billion – expected to grow 5% per year and reach USD 2,43 billion in 2035, according to our estimation – the Czech Republic’s OTC and pharma market is one of the most attractive markets in Central and Eastern Europe. The country’s high-quality infrastructure, the availability of cost-effective skilled labor, and regulations in sync with the EU are the primary explanations for the Czech self-medication and Rx industry’s growth. Generic medicines make up more than 30% of the total market share. Projections for growth in the economic, demographic, health expenditure and pharmaceutical market indicators are very positive for the Czech Republic, making it a very promising and stable market.
Chameleon Pharma Consulting Group has developed a systematic partner search process that can identify the most suitable local partner for you in the Czech Republic in only 10-12 weeks. Simply contact us for more details!
Czech Republic OTC and pharma market in 2035
USD 2,43 Billion
OTC and pharma market size, ex-factory
OTC and pharma market growth
Czech Republic in numbers
Interested in this market ?
We are ready to support you in Strategy, Marketing, Systematic International Company Partner Identification, Commercial Due Diligence, Business Development, Acquisition Search, Regulatory projects, and more in order to ensure your growth.